Skip to main content

Roser Solans Laque

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca

Roser Solans Laque

Institutions of which they are part

Main researcher
Systemic Diseases
Vall Hebron Institut de Recerca

Research lines

Risk factors for ischemic events in biopsy-proven Giant Cell Arteritis (GCA).

The study aims to investigate the risk factors for ischemic complications in patients with GCA, and the role that some endothelial growth factors may play in its development. This study is coordinated by Dr. Gonzalez Gay from University Hospital of Valdecilla, Santander.

IP: Roser Solans Laque

International Classification Criteria project for neuro-Behçet disease.

We are currently enrolled in this multicentre study coordinated by Dr. Seema Kalra from University Hospital of North Staffordshire (UK). The study aims to define new diagnostic criteria for neuro-Behçet disease. A set of neurologists, rheumatologists and specialists in Internal Medicine from different countries, experts in the diagnosis and management of this disease, will try to define a new set of diagnostic criteria based on clinical expertise, and in the most new laboratory and radiology modern tests.

IP: Roser Solans Laque

Genetic bases of Behçet disease.

We are currently enrolled in this multicentre study to investigate the possible influence of the genetic background in the disease pathogenesis, and to try to establish links between genetic variations and different clinical and biological patterns. The research is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute by sending samples from our cohort of patients along with the clinical data, and reviewing the results. It is supported by a SAS grant.

IP: Roser Solans Laque

Development and validation of a consensus of a systemic disease activity index for primary Sjögren’s syndrome. EULAR Sjögren’s Task Force.

We are currently enrolled in this multicentre study supported by the “EULAR Sjögren’s Task  Force”  to elaborate and agree on a systemic disease activity index for patients with primary Sjögren’s syndrome, that will be useful in the management of the disease. This study is coordinated by Dr. Raphaele Seror from the “Service de Rheumatologie Hôpital Bicêtre”, France.

IP: Roser Solans Laque

Projects

Ajuts Grups de Recerca (SGR) 2022

IP: Jaume Alijotas Reig
Collaborators: Moisés Labrador Horrillo, Carmen Pilar Simeón i Aznar, Anna Sala Cunill, Roser Solans Laque, Segundo Bujan Rivas, Mar Guilarte Clavero, Vicenç Fonollosa Pla, Fernando Martínez Valle, Victòria Cardona Dahl, Francesc Miro Mur, Alfredo Guillen Del Castillo, Albert Selva O'Callaghan, José Pardos Gea, Ariadna Anunciacion Llunell
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00048
Duration: 01/01/2022 - 30/06/2025

Autoimmunitat i Malaltia Trombòtica (GRC)

IP: Miguel Vilardell Tarres
Collaborators: Carmen Pilar Simeón i Aznar, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, Josefina Cortes Hernandez, Fernando Martínez Valle, Albert Selva O'Callaghan, Cristina Solé Marce
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 329
Duration: 01/01/2014 - 31/12/2016

Estudio clínico e inmunológico de la afección cardíaca en fase de remisión clínica de la Poliangeítis con Granulomatosis eosinofílica

IP: Roser Solans Laque
Collaborators: -
Funding agency: Mutual Mèdica de Catalunya i Balears
Funding: 4000
Reference: 2014\BMM\SOLANS
Duration: 27/11/2014 - 26/11/2015

Determinación del riesgo de afectación extraglandular y desarrollo de linfoma en el Síndrome de Sjögren primario mediante estudio de poblaciones linfocitarias y citocinas en sangre y tejido

IP: Roser Solans Laque
Collaborators: Carlos Palacio García, Margarita Alberola Ferranti, Fernando Martínez Valle
Funding agency: Instituto de Salud Carlos III
Funding: 35695
Reference: PI13/00655
Duration: 01/01/2014 - 30/06/2018

Related news

15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

Related professionals

Gerard Rubio Basagañas

Gerard Rubio Basagañas

EF- Cicle formatiu
Technological Infrastructure Unit
Digital Transformation Directorate
Read more
Sara Belmonte Calderon

Sara Belmonte Calderon

Research technician
Neurodegenerative Diseases
Read more
Luca Bollo

Luca Bollo

Predoctoral researcher
Clinical Neuroimmunology
Read more
Merce Albert Bayo

Merce Albert Bayo

Postdoctoral researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.